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Introduction: Irreversible electroporation (IRE) is a new minimally invasive tumor ablation technique which induces
irreversible disruption of cell membrane integrity by changing the transmembrane potential resulting in cell death.
Irreversible electroporation is currently undergoing clinical investigation as local tumor therapy for malignant liver
and lung lesions. This is the first case report to describe the successful palliative ablation of a presacral recurrence
of an endometrial cancer to achieve locoregional tumor control and pain relief.
Case presentation: A 56-year-old Caucasian woman was referred for interventional treatment of an advanced local
recurrence of endometrial cancer (11.9 × 11.6 × 14.9cm) with infiltration of the sacral bone and nerve plexus.
Due to the immediate proximity to the sacral plexus, the patient could neither undergo surgical therapy nor a
second radiation therapy. Due to its ablation mechanism irreversible electroporation was deemed to be the best
therapy option.
Conclusion: We showed in this case that a large tumor mass adjacent to a bundle of neural structures, the sacral
plexus, can be widely ablated by irreversible electroporation with only minor temporary impairment of the neural
function, even though a large infiltrating tissue volume (941cm3) was ablated.Introduction
Irreversible electroporation (IRE) is a new non-thermal
local ablative treatment procedure which induces the ir-
reversible permeabilization of a membrane lipid bilayer
by creation of nanopores resulting in cell death [1]. IRE
is currently undergoing clinical investigation as a locally
ablative tumor therapy for different organ systems, such
as kidney, lung or liver lesions [2].
Endometrial cancer represents the seventh most fre-
quent tumor worldwide in women with an annual inci-
dence of 142,000 patients worldwide [3]. The standard
therapy for endometrial cancer is total removal of the
uterus, cervix, as much as the parametrial tissue as
possible, and a wide margin of the vagina (Wertheim-
Meigs operation). At advanced stage endometrial cancer* Correspondence: christoph.niessen@klinik.uni-regensburg.de
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reproduction in any medium, provided the oradjuvant radiation is performed. Radiation is considered
standard therapy of inoperable tumor stages [4].
This article reports the successful palliative ablation of
a presacral recurrence of endometrial cancer as an indi-
vidual palliative therapy trial in order to achieve locore-
gional tumor control and pain relief.
Case presentation
A 56-year-old Caucasian woman was referred for treat-
ment of a local recurrence of endometrial cancer with
infiltration of her sacral bone and nerve plexus. After
initial diagnosis of endometrial cancer in 2005 (pT1B N0
MX G1 L0 V0), a Wertheim-Meigs operation was per-
formed with subsequent radiotherapy with the initial re-
sult of complete tumor remission. In 2009 the patient
presented with histologically confirmed pulmonary me-
tastases. Under anti-hormonal therapy (medroxyproges-
terone acetate), again complete remission was achieved.
At the start of 2012, 7 years after the initial diagnosis, the
patient was admitted to our hospital due to a presacrall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Baseline postcontrast T1-weighted magnetic resonance images (a: axial plane; b: sagittal plane). Preinterventional images
depicting the large (11.9 × 11.6 × 14.9 cm) viable tumor mass with infiltration and destruction of the os sacrum as well as infiltration of the sacral
nerve plexus.
Figure 2 Intraprocedural computed tomography fluoroscopy
image showing the six ablation electrodes in the tumor mass.
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widespread destruction of the os sacrum.
The patient complained of severe back pain and a
marked pain spreading out to her right leg, suggestive of
nerve infiltration. Magnetic resonance imaging (MRI)
showed infiltration of the os sacrum and the sacral plexus.
The tumor size was 11.9 × 11.6cm in axial section and
14.9cm in craniocaudal direction (Figure 1).
The patient’s case was discussed at the multidiscipli-
nary tumor board for therapy options: due to the imme-
diate proximity to the sacral plexus the patient could
neither undergo surgical therapy nor a second radiation
therapy because of the high risk of neural destruction
potentially resulting in paralysis. Due to its ablation
mechanism IRE was deemed to be the best therapy op-
tion for the patient as palliative disease control.
IRE uses a series of electrical pulses of microseconds to
generate irreversible permeabilization of cell membranes
and thereby induces cell death in the treated region. IRE
seems to be highly effective in tissues with a high density
of cell wall structures and less effective in tissues with a
high concentration of collagenous and elastic fibers [5,6].
This – in contrast to thermal ablation techniques like
radiofrequency ablation (RFA) or microwave ablation –
potentially allows tumor cell ablation without concomitant
destruction of connective tissue, blood vessels and nerves
[7]. Due to this potentially selective cell ablation technique,
IRE was offered as a palliative therapy option because it
provided the opportunity of tumor mass reduction and de-
crease of tumor burden with reduced risk of impairment
of the sacral plexus and surrounding blood vessels. The
procedure with risks and benefits was discussed with the
patient and informed consent was obtained.
The patient was put under general anesthesia and
neuromuscular blocking to prevent arrhythmia [8]. The
procedure was performed using a commercially availableIRE system. Due to the large tumor volume (941cm3) a
total of six needles were placed into the target area
(Figure 2). The percutaneous placement of the elec-
trodes was guided by computed tomography (CT) fluor-
oscopy as well as ultrasound using a multifrequency
probe (1 to 5MHz). As recommended by the manufac-
turer and recorded by the IRE generator the following
parameters were used: number of electrodes: six; type of
electrodes: monopolar; distance of electrodes: 0.7cm
(minimum), 1.2cm (maximum); impulses per electrode:
70; voltage: 1100V (minimum), 3000V (maximum). A
stepwise ablation procedure with multiple replacements of
the electrodes was performed, starting from a caudal pos-
ition and moving to cranial. The first ablation procedure
covered about 40% of the tumor mass and was stopped
after 8 hours. Follow-up imaging showed good response to
treatment in the caudal parts of the tumor with remaining
viable tumor tissue in the cranial parts (Figure 3). The pa-
tient was scheduled for a second ablation procedure after
14 weeks to cover the formally not treated areas.
Figure 3 Follow-up postcontrast T1-weighted magnetic resonance images at 24 hours after first intervention. Viable enhancing
tumor tissue (arrow) in the cranial and peripheral part of the lesion. Central parts of the tumor are necrotic (arrow heads). (a: axial plane,
b: sagittal plane).
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any cardiovascular events, in particular no supraventricu-
lar tachycardia and no atrial fibrillation. Complications,
especially postinterventional paralysis or bleeding, were
not observed. After the first ablation procedure the patient
did not complain about aggravated back pain; neither sen-
sory deficit, nor loss of strength in her legs, nor paresthe-
sia were observed. A neurological examination after the
second ablation session revealed a mild 4+ paresis of the
right extensor hallucis longus (L4 to S1) with com-
plete resolution after 4 weeks. No sensory loss or im-
pairment of bladder function occurred. After the second
intervention opiate medication could be withdrawn. Using
carbamazepine (200mg twice a day) and Polamidone
(levomethadone) (5mg three times a day) pain control was
achieved. The patient’s 24 hour follow-up imaging after
the second ablation as well as follow-up imaging (Figure 4)Figure 4 Follow-up postcontrast T1-weighted magnetic resonance
parts of the tumor mass show viable enhancing tumor tissue (arrow). C
b: sagittal plane).after 8 weeks (consisting of contrast-enhanced ultrasound,
MRI and a CT scan) showed wide ablation of the tumor
with necrosis of most portions of the tumor and reduction
of tumor volume to 791cm3.
Discussion
Among the different tumor ablation techniques RFA is
the most widespread technique [9]. Even though percu-
taneous ablation techniques are used as possibly curative
therapies, palliative tumor ablation can be useful to
achieve locoregional control of tumor growth, pain relief
or pain control, especially in patients with unresectable
tumor manifestations [10].
Due to heat dissipation to adjacent structures there is
an inherent risk of thermal damage of adjacent organs,
blood vessels and, of course, nerves. Thus, lesions close
to adjacent structures with high risk of unintended heatimages at 8 weeks after second intervention. Only peripheral
entral parts of the tumor are necrotic (arrow head). (a: axial plane,
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mal ablation techniques. IRE, in contrast to RFA, is a
non-thermal ablation technique of soft tissue and offers
a possibility to overcome the aforementioned limitations
of thermal ablations. Instead of using heat, IRE uses a
series of electrical pulses for microseconds to generate
irreversible permeabilization of cell membranes, presum-
ably through the formation of nanoscale defects in the
cell membrane, and thereby induces cell death in the
treated tissue.
IRE originally was viewed as an undesirable side effect
of reversible electroporation and therefore was studied
only to define the upper limit of electrical parameters
that induce reversible electroporation. Due to its various
features, for example transdermal delivery or introduc-
tion of drugs and genes into cells, or electrochemo-
therapy, reversible electroporation is an important
method in biotechnology and medicine [11]. Davalos,
Mir and Rubinsky in 2005 reported that IRE can be used
as an independent modality for ablation of substantial
tissue volumes [12]. Their findings were subsequently
confirmed in experimental studies on cells and in large
animal models [13,14].
In a series of studies, Lee could show that IRE pro-
duces irreversible tissue damage, which earlier was at-
tributed only to thermal effects [15]. Furthermore, IRE
proved to be especially effective in tissues with a high
density of cell wall structures and less effective in tissues
with a high concentration of collagenous and elastic fi-
bers, which is suggestive of a cell selective effect [5,6].
There appears to be complete ablation up to the margin
of blood vessels without compromising the functionality
of the blood vessels [16]. This – in contrast to thermal
ablation – would allow tumor cell ablation without con-
comitant destruction of connective tissue, blood vessels
and nerves, which means ablation of tumor cells in those
areas where thermal ablation was not possible before. In
the proximity of larger blood vessels thermal ablation
techniques are also hindered by the heat-sink effect. Due
to its cooling effect blood flow is an important determi-
nant as much as a limiting factor of thermal ablation
techniques [17,18]. IRE seems to be unaffected by the
blood flow and conversely does not potentially affect the
macrovascularization of the ablation zone [19].
Conclusion
Due to its more selective and non-thermal ablation ef-
fect IRE widens the field of minimally invasive treatable
lesions. We showed in this case report that a large ma-
lignant lesion adjacent to a bundle of neural structures,
that is the sacral plexus, can be widely ablated by IRE
with only minor, temporary impairment of the neural
function, even though a large infiltrating tissue volume
was ablated.Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
ages. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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